Methods and compositions for car T cell therapy

Patent metadata

Field	Value
Publication number	US-12144850-B2
Application number	US-201716092054-A
Country	US
Kind code	B2
Filing date	Apr 7, 2017
Priority date	Apr 8, 2016
Publication date	Nov 19, 2024
Grant date	Nov 19, 2024

Abstract

The present disclosure relates to methods of treating a patient with a cancer by administering to the patient a composition comprising CAR T cells and a small molecule linked to a targeting moiety by a linker. The disclosure also relates to compositions for use in such methods.

First claim

What is claimed is:

1. A method of treating a patient for cancer, the method comprising:
administering to the patient a chimeric antigen receptor T cell (CAR T cell) composition, wherein the CAR T cell comprises a chimeric antigen receptor (CAR) directed to fluorescein isothiocyanate (FITC), and
administering to the patient an effective amount of a first conjugate, or a pharmaceutically acceptable salt thereof, wherein the first conjugate comprises an NK-1 receptor-binding ligand (NK1RL) and FITC,
wherein the NK1RL is a small molecule comprising

wherein the CAR T cell comprises a nucleic acid comprising SEQ ID NO: 1 or SEQ ID NO: 3,
wherein the cancer is an NK-1 receptor-expressing cancer, and
wherein the patient is treated for cancer.

2. The method of claim 1 , further comprising administering to the patient an effective amount of a second conjugate, or a pharmaceutically acceptable salt thereof, wherein the second conjugate comprises a folate and FITC.

3. The method of claim 2 , wherein the first conjugate comprises a first divalent linker covalently bound to FITC and covalently bound to the NK1RL, and the second conjugate comprises is a second divalent linker covalently bound to FITC and covalently bound to the folate.

4. The method of claim 3 , wherein the first divalent linker and the second divalent linker each comprises polyethylene glycol (PEG).

5. The method of claim 2 , wherein the second conjugate is:

6. The method of claim 1 , wherein the cancer comprises a folate receptor-expressing cancer.

7. The method of claim 1 , wherein the first conjugate is:

8. A method of treating a patient for cancer, the method comprising:
administering to the patient a chimeric antigen receptor T cell (CAR T cell) composition, wherein the CAR T cell comprises a chimeric antigen receptor (CAR) directed to fluorescein isothiocyanate (FITC), and
administering to the patient an effective amount of a first conjugate, or a pharmaceutically acceptable salt thereof, wherein the first conjugate comprises an NK-1 receptor-binding ligand (NKIRL) and FITC,
wherein the NK1RL is a small molecule comprising

wherein the CAR T cell comprises a polypeptide comprising SEQ ID NO: 2,
wherein the cancer is an NK-1 receptor-expressing cancer, and
wherein the patient is treated for cancer.

9. The method of claim 8 , further comprising administering to the patient an effective amount of a second conjugate, or a pharmaceutically acceptable salt thereof, wherein the second conjugate comprises a folate and FITC.

10. The method of claim 9 , wherein the first conjugate comprises a first divalent linker covalently bound to FITC and covalently bound to the NK1RL, and the second conjugate comprises is a second divalent linker covalently bound to FITC and covalently bound to the folate.

11. The method of claim 10 , wherein the first divalent linker and the second divalent linker each comprises polyethylene glycol (PEG).

12. The method of claim 9 , wherein the second conjugate is:

13. The method of claim 8 , wherein the first conjugate is:

14. The method of claim 8 , wherein the cancer comprises a folate receptor-expressing cancer.

Assignees

• Purdue Research Foundation
• Endocyte Inc

Inventors

• Low Philip Stewart
• Chu Haiyan
• Lee Yong Gu

Classifications

• A61K40/4202

  Receptors, cell surface antigens or cell surface determinants · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2239/49

  Breast · CPC title

• A61K2239/31

  characterized by the route of administration · CPC title